Risk of Breast Cancer in Association with the Use of Second-generation Antipsychotics
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: Previous studies regarding the relationship between the risk of breast cancer (BC) and antipsychotics use have reported inconsistent findings. Insufficient sample size and/or observation period may have hindered revealing the risk of BC associated with antipsychotics use. We aimed to investigate whether the use of second-generation antipsychotics (SGA) is associated with increased risk of BC. Methods: We used the Health Insurance Review Agency database in South Korea between 2008 and 2018. The index date was determined as the date of the first antipsychotic prescription. We selected women prescribed SGAs for more than 30 days within a year from the index date and age-matched controls, yielding 498,970 cases and 997,940 controls. The Cox proportional hazards regression model was used for estimating the risk. Results: The incidence rates of BC were 109.74 and 101.51 per 100,000 person-years in the case and control groups, respectively. There was an increased risk of BC in the case group (hazard ratio [HR] = 1.08, 95% confidence interval [CI] 1.04−1.13). There was a higher risk of BC in subjects prescribed with ≥ 10,000 mg of olanzapine equivalent dose (HR = 1.29, 95% CI 1.14−1.46) than those with ＜ 10,000 mg (HR = 1.05, 95% CI 1.00−1.11). The increased risk of BC in the case group became significant after six years of the observation period (≥ 6 years: HR = 1.24, 95% CI 1.14−1.35, 3 to ＜ 6 years: HR = 1.06, 95% CI 0.97−1.15, ＜ 3 years: HR = 1.02, 95% CI 0.95−1.09). Conclusion: This study indicated that the use of SGAs is associated with increased risk of BC in a long-term relationship with a dose-response pattern.
Abstract
Objective: Previous studies regarding the relationship between the risk of breast cancer (BC) and antipsychotics use have reported inconsistent findings. Insufficient sample size and/or observation period may have hindered revealing the risk of BC associated with antipsychotics use. We aimed to investigate whether the use of second-generation antipsychotics (SGA) is associated with increased risk of BC. Methods: We used the Health Insurance Review Agency database in South Korea between 2008 and 2018. The index date was determined as the date of the first antipsychotic prescription. We selected women prescribed SGAs for more than 30 days within a year from the index date and age-matched controls, yielding 498,970 cases and 997,940 controls. The Cox proportional hazards regression model was used for estimating the risk. Results: The incidence rates of BC were 109.74 and 101.51 per 100,000 person-years in the case and control groups, respectively. There was an increased risk of BC in the case group (hazard ratio [HR] = 1.08, 95% confidence interval [CI] 1.04−1.13). There was a higher risk of BC in subjects prescribed with ≥ 10,000 mg of olanzapine equivalent dose (HR = 1.29, 95% CI 1.14−1.46) than those with ＜ 10,000 mg (HR = 1.05, 95% CI 1.00−1.11). The increased risk of BC in the case group became significant after six years of the observation period (≥ 6 years: HR = 1.24, 95% CI 1.14−1.35, 3 to ＜ 6 years: HR = 1.06, 95% CI 0.97−1.15, ＜ 3 years: HR = 1.02, 95% CI 0.95−1.09). Conclusion: This study indicated that the use of SGAs is associated with increased risk of BC in a long-term relationship with a dose-response pattern.
참고문헌 (28)
- Maher AR, "Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults : a systematic review and meta-analysis", JAMA, 306, pp.1359~1369 (2011)
- Li P, "Dopamine targeting drugs for the treatment of schizophrenia : past, present and future", Curr Top Med Chem, 16, pp.3385~3403 (2016)
- Bostwick JR, "Antipsychotic-induced hyperprolactinemia", Pharmacotherapy, 29, pp.64~73 (2009)
- Clevenger CV, "The role of prolactin in mammary carcinoma", Endocr Rev, 24, pp.1~27 (2003)
- Wang M, "Plasma prolactin and breast cancer risk : a meta-analysis", Sci Rep, 6, pp.25998~ (2016)
- Johnston AN, "Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions", Breast Cancer Res, 20, pp.42~ (2018)
- Zhang W, "Antiproliferative activities of the second-generation antipsychotic drug sertindole against breast cancers with a potential application for treatment of breast-to-brain metastases", Sci Rep, 8, pp.15753~ (2018)
- De Hert M, "Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia : a critical review", Acta Psychiatr Scand, 133, pp.5~22 (2016)
- Wang PS, "Dopamine antagonists and the development of breast cancer", Arch Gen Psychiatry, 59, pp.1147~1154 (2002)
- Sun WW, "The central mechanism of risperidone-induced hyperprolactinemia", Prog Neuropsychopharmacol Biol Psychiatry, 76, pp.134~139 (2017)
- Reutfors J, "Risk of breast cancer in risperidone users : a nationwide cohort study", Schizophr Res, 182, pp.98~103 (2017)
- Azoulay L, "The use of atypical antipsychotics and the risk of breast cancer", Breast Cancer Res Treat, 129, pp.541~548 (2011)
- Pottegård A, "Use of antipsychotics and risk of breast cancer : a Danish nationwide case-control study", Br J Clin Pharmacol, 84, pp.2152~2161 (2018)
- Dalton SO, "Cancer risk among users of neuroleptic medication : a population-based cohort study", Br J Cancer, 95, pp.934~939 (2006)
- 김지애, "Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data", Journal of Korean Medical Science, 32(5), pp.718~728 (2017), 대한의학회
- Peuskens J, "The effects of novel and newly approved antipsychotics on serum prolactin levels : a comprehensive review", CNS Drugs, 28, pp.421~453 (2014)
- Leucht S, "Dose equivalents for antipsychotic drugs : the DDD method", Schizophr Bull, 42(Suppl 1), pp.S90~S94 (2016)
- Kanhouwa S, "Phenothiazines and breast cancer", J Natl Med Assoc, 76, pp.785~788 (1984)
- Kelly JP, "Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines", Am J Epidemiol, 150, pp.861~868 (1999)
- George A, "Psychotropic medication use and postmenopausal breast cancer risk", Cancer Epidemiol Biomarkers Prev, 29, pp.254~256 (2020)
- Tsai KY, "Risperidone exposure and breast cancer risk: a cohort study using the Taiwan national health insurance research database", Neuropsychiatry(London), 8, pp.1549~1558 (2018)
- Reynolds C, "Expression of prolactin and its receptor in human breast carcinoma", Endocrinology, 138, pp.5555~5560 (1997)
- Li Y, "Stabilization of prolactin receptor in breast cancer cells", Oncogene, 25, pp.1896~1902 (2006)
- Badran A, "Antipsychotics drug aripiprazole as a lead against breast cancer cell line(MCF-7)in vitro", PLoS One, 15, pp.e0235676~ (2020)
- Maeshima T, "Effect of antipsychotics on breast tumors by analysis of the Japanese Adverse Drug Event Report database and cell-based experiments", J Pharm Health Care Sci, 7, pp.13~ (2021)
- Song Y, "Thioridazine hydrochloride : an antipsychotic agent that inhibits tumor growth and lung metastasis in triple-negative breast cancer via inducing G0", G1 arrest and apoptosis, 2020, pp.19, 3521~3533
- Moysich KB, "Use of common medications and breast cancer risk", Cancer Epidemiol Biomarkers Prev, 17, pp.1564~1595 (2008)
- Jungbauer J, "The disregarded caregivers : subjective burden in spouses of schizophrenia patients", Schizophr Bull, 30, pp.665~675 (2004)